PARP7-IN-22
PARP7-IN-22 (XLY-1) is a PARP7 inhibitor with an IC50 of 0.6 nM. PARP7-IN-22 (XLY-1) is orally active, enhances type I interferon signaling in vitro, restores type I interferon signaling, promotes T cell infiltration into tumor tissues, and significantly inhibits tumor growth. PARP7-IN-22 shows promise for research in the field of cancer immunotherapy[1].
Product Specifications
CAS Number
[2946705-91-3]
UNSPSC
12352005
Target
PARP
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/parp7-in-22.html
Purity
99.59
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1NN=CC(NCCCCNC(N2CCN(CC2)C3=NC=C(C(F)(F)F)C=N3)=O)=C1C(F)(F)F
Molecular Formula
C19H22F6N8O2
Molecular Weight
508.42
References & Citations
[1]Yang J, et al. Discovery of highly potent PARP7 inhibitors for cancer immunotherapy[J]. Bioorganic Chemistry, 2024, 148: 107469.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PARP7
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Recombinant Ehrlichia chaffeensis Protoheme IX farnesyltransferase (ctaB), partial
![Human Monoclonal CD19 Antibody (Immunomedics hA19) [CoraFluor 1]](https://cdn.genprice.uk/genprice/uk/genprice2.webp)
Human Monoclonal CD19 Antibody (Immunomedics hA19) [CoraFluor 1]
